Edition:
United Kingdom

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

50.05USD
18 May 2018
Change (% chg)

$2.15 (+4.49%)
Prev Close
$47.90
Open
$48.15
Day's High
$50.75
Day's Low
$47.85
Volume
223,079
Avg. Vol
260,035
52-wk High
$50.75
52-wk Low
$11.80

Chart for

About

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or... (more)

Overall

Beta: --
Market Cap(Mil.): $495.06
Shares Outstanding(Mil.): 30.56
Dividend: --
Yield (%): --

Financials

  ATRA.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -3.33 -- --
ROI: -36.94 1.57 14.38
ROE: -37.81 2.43 16.07

BRIEF-Atara Biotherapeutics Reports Q1 Loss Per Share $1.05

* ATARA BIOTHERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

08 May 2018

BRIEF-Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration

* ATARA BIOTHERAPEUTICS EXPANDS T-CELL IMMUNOTHERAPY COLLABORATION TO ADVANCE NEXT-GENERATION CAR T TECHNOLOGIES IN ONCOLOGY, AUTOIMMUNE AND OTHER DISEASES Source text for Eikon: Further company coverage:

08 May 2018

BRIEF-Atara Biotherapeutics prices public offering of stock at $35 per share​

* ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

01 Mar 2018

BRIEF-Atara Biotherapeutics Files For Potential Mixed Shelf Offering

* ATARA BIOTHERAPEUTICS INC FILES FOR A POTENTIAL MIXED SHELF OFFERING; SIZE UNDISCLOSED - SEC FILING ‍​ Source text (http://bit.ly/2CKPbcB) Further company coverage:

27 Feb 2018

BRIEF-Atara Says Commenced Underwritten Public Offering Of $150 Mln Shares Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

27 Feb 2018

BRIEF-Atara Biotherapeutics Posts Q4 Loss Of $1.15 Per Share

* ATARA BIOTHERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

27 Feb 2018

BRIEF-Atara Biotherapeutics Says CFO Intends To Retire In April 2018

* ATARA BIOTHERAPEUTICS ANNOUNCES CHIEF FINANCIAL OFFICER INTENTION TO RETIRE IN APRIL 2018

21 Feb 2018

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS

10 Jan 2018

BRIEF-Camber Capital Management Reports 6.7 Pct Passive Stake In Atara Biotherapeutics

* CAMBER CAPITAL MANAGEMENT LLC REPORTS A 6.7 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS AS OF JANUARY 04 - SEC FILING Source text : ( http://bit.ly/2m1PfiG ) Further company coverage:

05 Jan 2018

BRIEF-Atara Biotherapeutics Announces Proposed Offering Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

02 Jan 2018

Competitors

  Price Chg
Biogen Inc (BIIB.OQ) $280.40 -0.17
Bayer AG (BAYGn.DE) €104.36 -0.14
Bayer AG (BAYE.F) -- --
Teva Pharmaceutical Industries Limited (TEVA.TA) 7,580.00 +61.00
Merck KGaA (MRCG.DE) €85.00 -1.04
Sanofi SA (SASY.PA) €66.44 +0.32
Novartis AG (NOVN.S) CHF77.00 -0.64
Roche Holding Ltd. (ROG.S) CHF224.55 +0.55
Roche Holding Ltd. (RO.S) CHF229.20 +1.00

Earnings vs. Estimates